Abstract
One of most promising strategies for cancer immunotherapy is immune checkpoint blockade. However, the remarkable responses to the therapy are currently limited to a minority of patients and indications, highlighting the importance of understanding of immune mechanisms. The purpose of this study was to investigate the effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
